Finoriq research workspace
Allarity Therapeutics, Inc. (ALLR) SEC Filings & Filing Highlights
Allarity Therapeutics, Inc. develops drugs for the personalized treatment of cancer using. Review ALLR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
- Company
- Allarity Therapeutics, Inc. (ALLR)
- Ticker
- ALLR
- Market Cap
- $18.2M
- Latest Price
- $1.1799
- Industry
- Biotech & Pharma
Allarity Therapeutics, Inc. (ALLR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Allarity Therapeutics, Inc. (ALLR).
| Event | Form | Date |
|---|---|---|
| Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Comp...Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic | 8-K8.01 | 2026-07-01 |
| The final voting results for each proposal are set forth below. For additional information rega...On June 26, 2026, Allarity Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual... | 8-K5.07 | 2026-07-01 |
| Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO G...Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 | 8-K8.01 | 2026-06-22 |
| Allarity Therapeutics, Inc.: Management or board changeAs previously disclosed, effective June 1, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Manage... | 8-K5.02 | 2026-06-02 |
| Our DRP ® Companion Diagnostics PlatformCopyright © 2023 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Dual inhibition of PARP and WNT: A novel drug - biomarker combina... | 8-K8.01 | 2026-05-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.